Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

LONDON - GSK plc announced significant overall survival (OS) results from the DREAMM-7 trial, which showed a 42% reduction in the risk of death for patients treated with Blenrep (belantamab ...

GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...

GSK’s antibody-drug conjugate Blenrep looked like a breakthrough in multiple myeloma when it was approved in 2020, even as a fifth-line treatment for the difficult blood cancer. Just two years ...

Regulatory submission supported by phase III head-to-head DREAMM-7 trial showing statistically significant efficacy, including overall survival If approved, Blenrep combination could redefine ...

Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse · Data build on findings from DREAMM-7 and DREAMM-8 and ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at ...

LONDON - GSK (LON:GSK) plc announced significant overall survival (OS) results from the DREAMM-7 trial, which showed a 42% reduction in the risk of death for patients treated with Blenrep (belantamab ...

LONDON - GSK plc (LSE/NYSE: GSK) announced Monday that the National Medical (TASE:PMCN) Products Administration (NMPA) of China has accepted the new drug application for Blenrep (belantamab ...

Clinical trial investigators and the company believe these results could support making the GSK drug, Blenrep, a new standard of care treatment for this type of blood cancer. The new trial results ...